|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nand M, Maiti P, Pant R, Kumari M, Chandra
S and Pande V: Virtual screening of natural compounds as inhibitors
of EGFR 696–1022 T790M associated with non-small cell lung cancer.
Bioinformation. 12:311–317. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Remon J, Besse B and Soria JC: Successes
and failures: What did we learn from recent first-line treatment
immunotherapy trials in non-small cell lung cancer? BMC Med.
15:552017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hynes NE and Lane HA: ERBB receptors and
cancer: The complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hirsch FR, Varella-Garcia M, Bunn PA Jr,
Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C and Franklin WA:
Epidermal growth factor receptor in non-small-cell lung carcinomas:
Correlation between gene copy number and protein expression and
impact on prognosis. J Clin Oncol. 21:3798–3807. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Suzuki S, Dobashi Y, Sakurai H, Nishikawa
K, Hanawa M and Ooi A: Protein overexpression and gene
amplification of epidermal growth factor receptor in nonsmall cell
lung carcinomas. An immunohistochemical and fluorescence in situ
hybridization study. Cancer. 103:1265–1273. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Woodburn JR: The epidermal growth factor
receptor and its inhibition in cancer therapy. Pharmacol Ther.
82:241–250. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wakeling AE, Guy SP, Woodburn JR, Ashton
SE, Curry BJ, Barker AJ and Gibson KH: ZD1839 (Iressa): An orally
active inhibitor of epidermal growth factor signaling with
potential for cancer therapy. Cancer Res. 62:5749–5754.
2002.PubMed/NCBI
|
|
9
|
Inoue A, Suzuki T, Fukuhara T, Maemondo M,
Kimura Y, Morikawa N, Watanabe H, Saijo Y and Nukiwa T: Prospective
phase II study of gefitinib for chemotherapy-naive patients with
advanced non-small-cell lung cancer with epidermal growth factor
receptor gene mutations. J Clin Oncol. 24:3340–3346. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sonobe M, Manabe T, Wada H and Tanaka F:
Mutations in the epidermal growth factor receptor gene are linked
to smoking-independent, lung adenocarcinoma. Br J Cancer.
93:355–363. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Costa DB, Schumer ST, Tenen DG and
Kobayashi S: Differential responses to erlotinib in epidermal
growth factor receptor (EGFR)-mutated lung cancers with acquired
resistance to gefitinib carrying the L747S or T790M secondary
mutations. J Clin Oncol. 26:1184–1186. 2008. View Article : Google Scholar
|
|
12
|
Rolfo C, Caglevic C, Santarpia M, Araujo
A, Giovannetti E, Gallardo CD, Pauwels P and Mahave M:
Immunotherapy in NSCLC: A Promising and Revolutionary Weapon. Adv
Exp Med Biol. 995:97–125. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang J, Jia Y, Zhao S, Zhang X, Wang X,
Han X, Wang Y, Ma M, Shi J and Liu L: BIN1 reverses PD-L1-mediated
immune escape by inactivating the c-MYC and EGFR/MAPK signaling
pathways in non-small cell lung cancer. Oncogene. 36:6235–6243.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lenschow DJ, Walunas TL and Bluestone JA:
CD28/B7 system of T cell costimulation. Annu Rev Immunol.
14:233–258. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dong H and Chen L: B7-H1 pathway and its
role in the evasion of tumor immunity. J Mol Med (Berl).
81:281–287. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kryczek I, Wei S, Zhu G, Myers L, Mottram
P, Cheng P, Chen L, Coukos G and Zou W: Relationship between B7-H4,
regulatory T cells, and patient outcome in human ovarian carcinoma.
Cancer Res. 67:8900–8905. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Inamura K, Yokouchi Y, Kobayashi M,
Sakakibara R, Ninomiya H, Subat S, Nagano H, Nomura K, Okumura S,
Shibutani T and Ishikawa Y: Tumor B7-H3 (CD276) expression and
smoking history in relation to lung adenocarcinoma prognosis. Lung
Cancer. 103:44–51. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu Y, Yao S, Iliopoulou BP, Han X,
Augustine MM, Xu H, Phennicie RT, Flies SJ, Broadwater M and Ruff
Wetal: B7-H5 costimulates human T cells via CD28H. Nat Commun.
4:20432013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Byers JT, Paniccia A, Kaplan J, Koenig M,
Kahn N, Wilson L, Chen L, Schulick RD, Edil BH and Zhu Y:
Expression of the Novel Costimulatory Molecule B7-H5 in Pancreatic
Cancer. Ann Surg Oncol. 22 Suppl 3:S1574–S1579. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen L: Co-inhibitory molecules of the
B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol.
4:336–347. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Woodland DL and Kohlmeier JE: Migration,
maintenance and recall of memory T cells in peripheral tissues. Nat
Rev Immunol. 9:153–161. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Katayama A, Ogino T, Bandoh N, Nonaka S
and Harabuchi Y: Expression of CXCR4 and its down-regulation by
IFN-gamma in head and neck squamous cell carcinoma. Clin Cancer
Res. 11:2937–2946. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Muller A, Homey B, Soto H, Ge N, Catron D,
Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al:
Involvement of chemokine receptors in breast cancer metastasis.
Nature. 410:50–56. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ghebeh H, Mohammed S, Al-Omair A, Qattan
A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Bin Amer S, Tulbah
A, et al: The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is
expressed in breast cancer patients with infiltrating ductal
carcinoma: Correlation with important high-risk prognostic factors.
Neoplasia. 8:190–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hamanishi J, Mandai M, Iwasaki M, Okazaki
T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N,
et al: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+
T lymphocytes are prognostic factors of human ovarian cancer. Proc
Natl Acad Sci USA. 104:pp. 3360–3365. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun J, Xu K, Wu C, Wang Y, Hu Y, Zhu Y,
Chen Y, Shi Q, Yu G and Zhang X: PD-L1 expression analysis in
gastric carcinoma tissue and blocking of tumor-associated PD-L1
signaling by two functional monoclonal antibodies. Tissue Antigens.
69:19–27. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun Y, Wang Y, Zhao J, Gu M, Giscombe R,
Lefvert AK and Wang X: B7-H3 and B7-H4 expression in non-small-cell
lung cancer. Lung Cancer. 53:143–151. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ghebeh H, Barhoush E, Tulbah A, Elkum N,
Al-Tweigeri T and Dermime S: FOXP3+ Tregs and B7-H1+/PD-1+ T
lymphocytes co-infiltrate the tumor tissues of high-risk breast
cancer patients: Implication for immunotherapy. BMC cancer.
8:572008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pettit SJ, Ali S, O'Flaherty E, Griffiths
TR, Neal DE and Kirby JA: Bladder cancer immunogenicity: Expression
of CD80 and CD86 is insufficient to allow primary CD4+ T cell
activation in vitro. Clin Exp Immunol. 116:48–56. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Freeman GJ, Long AJ, Iwai Y, Bourque K,
Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne
MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a
novel B7 family member leads to negative regulation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim S, Buchlis G, Fridlender ZG, Sun J,
Kapoor V, Cheng G, Haas A, Cheung HK, Zhang X and Corbley Metal:
Systemic blockade of transforming growth factor-beta signaling
augments the efficacy of immunogene therapy. Cancer Res.
68:10247–10256. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gaspar NJ, Li L, Kapoun AM, Medicherla S,
Reddy M, Li G, O'Young G, Quon D, Henson M and Damm D Letal:
Inhibition of transforming growth factor beta signaling reduces
pancreatic adenocarcinoma growth and invasiveness. Mol Pharmacol.
72:152–161. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Erkanli S, Bolat F, Kayaselcuk F, Demirhan
B and Kuscu E: COX-2 and survivin are overexpressed and positively
correlated in endometrial carcinoma. Gynecol Oncol. 104:320–325.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li MO, Sanjabi S and Flavell RA:
Transforming growth factor-beta controls development, homeostasis,
and tolerance of T cells by regulatory T cell-dependent and
-independent mechanisms. Immunity. 25:455–471. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hoechst B, Ormandy LA, Ballmaier M, Lehner
F, Kruger C, Manns MP, Greten TF and Korangy F: A new population of
myeloid-derived suppressor cells in hepatocellular carcinoma
patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology.
135:234–243. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kopfstein L, Veikkola T, Djonov VG,
Baeriswyl V, Schomber T, Strittmatter K, Stacker SA, Achen MG,
Alitalo K and Christofori G: Distinct roles of vascular endothelial
growth factor-D in lymphangiogenesis and metastasis. Am J Pathol.
170:1348–1361. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kamstock D, Elmslie R, Thamm D and Dow S:
Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue
sarcoma. Cancer Immunol Immunother. 56:1299–1309. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu XH, Kirschenbaum A, Yu K, Yao S and
Levine AC: Cyclooxygenase-2 suppresses hypoxia-induced apoptosis
via a combination of direct and indirect inhibition of p53 activity
in a human prostate cancer cell line. J Biol Chem. 280:3817–3823.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bahrenberg G, Behrmann I, Barthel A,
Hekerman P, Heinrich PC, Joost HG and Becker W: Identification of
the critical sequence elements in the cytoplasmic domain of leptin
receptor isoforms required for Janus kinase/signal transducer and
activator of transcription activation by receptor heterodimers. Mol
Endocrinol. 16:859–872. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bjorbaek C, Uotani S, da Silva B and Flier
JS: Divergent signaling capacities of the long and short isoforms
of the leptin receptor. J Biol Chem. 272:32686–32695. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kanda N, Seno H, Konda Y, Marusawa H,
Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T and Uenoyama
Yetal: STAT3 is constitutively activated and supports cell survival
in association with survivin expression in gastric cancer cells.
Oncogene. 23:4921–4929. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Du XL, Yang H, Liu SG, Luo ML, Hao JJ,
Zhang Y, Lin DC, Xu X, Cai Y, Zhan QM and Wang MR: Calreticulin
promotes cell motility and enhances resistance to anoikis through
STAT3-CTTN-Akt pathway in esophageal squamous cell carcinoma.
Oncogene. 28:3714–3722. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang X, Zhang J, Wang L, Wei H and Tian
Z: Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human
lung cancer in xenograft mice. BMC Cancer. 7:1492007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Huang WT, Yang SF, Wu CC, Chen WT, Huang
YC, Su YC and Chai CY: Expression of signal transducer and
activator of transcription 3 and suppressor of cytokine signaling 3
in urothelial carcinoma. Kaohsiung J Med Sci. 25:640–646. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yakata Y, Nakayama T, Yoshizaki A, Kusaba
T, Inoue K and Sekine I: Expression of p-STAT3 in human gastric
carcinoma: Significant correlation in tumour invasion and
prognosis. Int J Oncol. 30:437–442. 2007.PubMed/NCBI
|
|
47
|
Huang S: Regulation of metastases by
signal transducer and activator of transcription 3 signaling
pathway: Clinical implications. Clin Cancer Res. 13:1362–1366.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang W, Pang Q, Yan C, Wang Q, Yang J, Yu
S, Liu X, Yuan Z, Wang P and Xiao Z: Induction of PD-L1 expression
by epidermal growth factor receptor-mediated signaling in
esophageal squamous cell carcinoma. Onco Targets Ther. 10:763–771.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lim SO, Li CW, Xia W, Lee HH, Chang SS,
Shen J, Hsu JL, Raftery D, Djukovic D and Gu Hetal: EGFR signaling
enhances aerobic glycolysis in triple-negative breast cancer cells
to promote tumor growth and immune escape. Cancer Res.
76:1284–1296. 2016. View Article : Google Scholar : PubMed/NCBI
|
